Partner Fund Management Lp Decreased Inogen Inc (NASDAQ:INGN) Stake By $17.76 Million

February 23, 2018 - By Max Morgan

Investors sentiment decreased to 1.2 in 2017 Q3. Its down 0.31, from 1.51 in 2017Q2. It turned negative, as 14 investors sold INGN shares while 65 reduced holdings. 37 funds opened positions while 58 raised stakes. 20.61 million shares or 0.71% less from 20.76 million shares in 2017Q2 were reported. 26,498 were reported by California Public Employees Retirement System. Natl Bank Of America De owns 32,047 shares. Deutsche Bancorporation Ag invested in 98,113 shares or 0.01% of the stock. Oberweis Asset Mngmt Inc reported 1.55% stake. Goldman Sachs Grp has invested 0% of its portfolio in Inogen, Inc. (NASDAQ:INGN). Laurion Capital Lp has 0% invested in Inogen, Inc. (NASDAQ:INGN). Driehaus Limited Co reported 183,932 shares. Eqis Mngmt Inc invested in 4,565 shares. Chicago Equity Limited Company has 16,125 shares. Millennium Ltd Llc holds 0.01% of its portfolio in Inogen, Inc. (NASDAQ:INGN) for 43,212 shares. Tower Research Cap Limited Liability (Trc) reported 2,504 shares. West Coast Fincl Limited Com reported 0.06% in Inogen, Inc. (NASDAQ:INGN). Dorsey & Whitney Co Lc reported 0.05% stake. Thornburg Investment Mngmt Inc reported 53,791 shares or 0.04% of all its holdings. Grp One Trading Lp owns 1,968 shares or 0% of their US portfolio.

Christopher Medlock James decreased its stake in Inogen Inc (NASDAQ:INGN) by 61.91% based on its latest 2017Q4 regulatory filing with the SEC. Partner Fund Management Lp sold 149,228 shares as the company’s stock rose 21.32% with the market. The hedge fund run by Christopher Medlock James held 91,829 shares of the health care company at the end of 2017Q4, valued at $10.94M, down from 241,057 at the end of the previous reported quarter. Partner Fund Management Lp who had been investing in Inogen Inc for a number of months, seems to be less bullish one the $2.73B market cap company. The stock increased 0.98% or $1.27 during the last trading session, reaching $130.76. About 38,552 shares traded. Inogen, Inc. (NASDAQ:INGN) has risen 88.09% since February 23, 2017 and is uptrending. It has outperformed by 71.39% the S&P500.

Partner Fund Management Lp, which manages about $4.22 billion US Long portfolio, upped its stake in Merit Med Sys Inc (NASDAQ:MMSI) by 491,641 shares to 1.20 million shares, valued at $51.80 million in 2017Q4, according to the filing. It also increased its holding in Molina Healthcare Inc (NYSE:MOH) by 684,477 shares in the quarter, for a total of 1.17M shares, and has risen its stake in Coupa Software Inc ().

The Jame’s Partner Fund Management firm of Christopher Medlock is based in San Francisco and was created in 2004. Four funds are managed under its wings.

Inogen, Inc. (NASDAQ:INGN) Ratings Coverage

Among 7 analysts covering Inogen (NASDAQ:INGN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inogen had 17 analyst reports since August 12, 2015 according to SRatingsIntel. The stock has “Buy” rating by Needham on Wednesday, November 8. The rating was maintained by Leerink Swann on Wednesday, August 12 with “Buy”. Piper Jaffray maintained the shares of INGN in report on Friday, August 4 with “Hold” rating. The company was upgraded on Tuesday, February 20 by Piper Jaffray. The firm has “Buy” rating by Needham given on Friday, August 4. The firm has “Buy” rating given on Thursday, June 8 by Needham. The rating was initiated by JP Morgan on Wednesday, July 13 with “Overweight”. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, September 22. On Wednesday, August 30 the stock rating was maintained by Needham with “Buy”. PiperJaffray upgraded the shares of INGN in report on Tuesday, February 20 to “Overweight” rating.

Inogen, Inc., a medical technology company, primarily develops, makes, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company has market cap of $2.73 billion. The companyÂ’s oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It has a 106.22 P/E ratio. It offers Inogen One systems, which are portable devices that concentrate the air around the patients to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories.

More notable recent Inogen, Inc. (NASDAQ:INGN) news were published by: Nasdaq.com which released: “Commit To Purchase Inogen At $100, Earn 6.1% Annualized Using Options” on February 23, 2018, also Businesswire.com with their article: “Inogen to Announce Fourth Quarter and Full Year 2017 Financial Results on …” published on January 24, 2018, Zacks.com published: “Inogen (INGN) Gains on Diverse Product Line, Competition Rife” on February 15, 2018. More interesting news about Inogen, Inc. (NASDAQ:INGN) were released by: Nasdaq.com and their article: “Validea’s Top Five Healthcare Stocks Based On Motley Fool – 2/18/2018” published on February 18, 2018 as well as Zacks.com‘s news article titled: “Is a Beat in Store for Inogen (INGN) This Earnings Season?” with publication date: February 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: